Login to Your Account

Pharma: Clinic Roundup

Monday, August 6, 2012
• Pfizer Inc., of New York, reported that a Phase IV study assessing the efficacy and safety of Toviaz (fesoterodine fumarate) in patients with overactive bladder met its primary endpoint of reducing urge urinary incontinence (UUI).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription